The global empagliflozin, dapagliflozin, and canagliflozin market is driven by the increasing prevalence of type 2 diabetes mellitus (T2DM), which affects an estimated 537 million adults globally as of 2021, a figure projected to rise to 783 million by 2045, according to the International Diabetes Federation (IDF). These sodium-glucose cotransporter-2 (SGLT2) inhibitors have gained traction due to their proven efficacy in reducing cardiovascular risks and managing chronic kidney disease (CKD), conditions that affect a significant portion of diabetic patients. For instance, nearly 40% of individuals with diabetes develop CKD, further highlighting the importance of these therapies. Additionally, advancements in combination therapies, such as those pairing SGLT2 inhibitors with metformin or DPP-4 inhibitors, have enhanced patient compliance and outcomes, broadening the market's potential. The growing burden of diabetes-related complications worldwide is expected to sustain the demand for these drugs in both developed and emerging markets.
